Department of Radiation Oncology, Fujian Children's Hospital (Fujian Branch of Shanghai Children's Medical Center), College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics,, Fujian Medical University, Fuzhou, China.
Department of Hematology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Int J Clin Oncol. 2024 Nov;29(11):1704-1714. doi: 10.1007/s10147-024-02610-3. Epub 2024 Aug 30.
Pineoblastoma (PB) represents a great challenge for clinical management due to lack of a specific therapeutic regimen. This study aims to identify relevant prognostic factors and potential treatment targets by mining public databases.
The clinical characteristics and survival data of PB patients were obtained from the SEER database between 2000 and 2019 for Cox regression analysis and nomogram construction. The PB's DNA methylation data was acquired from two GEO datasets, GSE133801 and GSE215240, for bioinformatics analysis.
Of 383 PB patients, Cox univariate analysis unveiled that male gender (p = 0.017), age younger than 3 years at diagnosis (p < 0.001) and absence of radiotherapy (p < 0.001) correlated with poorer overall survival (OS), the subsequent multivariate analysis confirmed sex (p = 0.036), age (p < 0.001) and radiotherapy (p = 0.005) as independent prognostic factors for OS. A nomogram showed robust predictive accuracy as evidenced by AUC values (1-year OS: 0.774, 3-year OS: 0.692, 5-year OS: 0.643). DNA methylation analysis observed tumor hypomethylation, notably in promoter regions. Later, the GO enrichment analysis of aberrantly methylated genes indicated associations with embryonic organ development, cellular membrane composition and DNA-binding transcription, while KEGG analysis revealed enrichment in tumor-associated MAPK, calcium and RAS signaling pathways.
The prognosis of PB is closely associated with sex, age and receipt of radiotherapy, potentially linked to aberrations in the RAS and MAPK signaling pathways. The individual case suggests that dasatinib and trametinib are potential targeted therapies for improving PB prognosis.
由于缺乏特定的治疗方案,松果体母细胞瘤(PB)的临床管理极具挑战性。本研究旨在通过挖掘公共数据库来确定相关的预后因素和潜在的治疗靶点。
从 2000 年至 2019 年,SEER 数据库中获取了 PB 患者的临床特征和生存数据,进行 Cox 回归分析和列线图构建。从两个 GEO 数据集 GSE133801 和 GSE215240 中获取 PB 的 DNA 甲基化数据,进行生物信息学分析。
在 383 名 PB 患者中,Cox 单因素分析显示,男性(p=0.017)、诊断时年龄小于 3 岁(p<0.001)和未接受放疗(p<0.001)与总生存期(OS)较差相关,随后的多因素分析证实性别(p=0.036)、年龄(p<0.001)和放疗(p=0.005)是 OS 的独立预后因素。列线图显示出稳健的预测准确性,AUC 值为(1 年 OS:0.774,3 年 OS:0.692,5 年 OS:0.643)。DNA 甲基化分析观察到肿瘤低甲基化,特别是在启动子区域。随后,异常甲基化基因的 GO 富集分析表明与胚胎器官发育、细胞膜组成和 DNA 结合转录有关,而 KEGG 分析显示肿瘤相关的 MAPK、钙和 RAS 信号通路富集。
PB 的预后与性别、年龄和放疗密切相关,可能与 RAS 和 MAPK 信号通路的异常有关。个体病例表明,达沙替尼和曲美替尼可能是改善 PB 预后的潜在靶向治疗方法。